Value of biologic therapy: A forecasting model in three disease areas

References

• Centers for Medicare and Medicaid Services, office of the actuary, national health statistics group, national health expenditures data files for downloading. Available at: http://www.cms.hhs.gov/NationalHealthExpendData/02_NationalHealthAccountsHistorical.asp#TopOfPage [Last accessed 29 February 2008]
   Google Scholar
• Bloom D, Canning D, Sevilla J. The Effect of Health on Economic Growth: Theory and Evidence. Cambridge, MA: National Bureau of Economic Research, 2001
   Google Scholar
• Cutler DM, McClellan M. Is technological change in medicine worth it?. Health Aff (Millwood) 2001;20:11-29
   Web of Science ®Google Scholar
• Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960–2000. N Engl J Med 2006;355:920-7
   PubMed Web of Science ®Google Scholar
• Goldman DP, Shang B, Bhattacharya J, et al. Consequences of health trends and medical innovation for the future elderly. Health Aff (Millwood) 2005;24(Suppl. 2):W5R-17
   Google Scholar
• Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff (Millwood) 2001;20:241-51
   PubMed Web of Science ®Google Scholar
• Lubitz J, Cai L, Kramarow E, et al. Health, life expectancy, and health care spending among the elderly. N Engl J Med 2003;349:1048-55
   PubMed Web of Science ®Google Scholar
• Luce BR, Mauskopf J, Sloan FA, et al. The return on investment in health care: from 1980 to 2000. Value Health 2006;9:146-56
   PubMed Web of Science ®Google Scholar
• Murphy K, Topel R. The Economic Value of Medical Research. Chicago, IL: University of Chicago Graduate School of Business, 1998
   Google Scholar
• Murphy K, Topel R. Diminishing returns? The costs and benefits of improving health. Perspect Biol Med 2003;46:S108-28
   PubMed Web of Science ®Google Scholar
• Murphy K, Topel R. The value of health and longevity. J Pol Econ 2006;114:871-904
   Web of Science ®Google Scholar
• Nordhaus W. The health of nations: the contribution of improved health to living standards. New Haven, CT: Cowles Foundation for Research in Economics at Yale University, Cowles Foundation Discussion Paper No. 1355, 2002
   Google Scholar
• Hay JW. Where's the value in health care?. Value Health 2006;9:141-3
   PubMed Web of Science ®Google Scholar
• Zhou H. Biologics in the pipeline: large molecules with high hopes or bigger risks?. J Clin Pharmacol 2007;47:550-2
   PubMed Web of Science ®Google Scholar
• Simon F. Market access for biopharmaceuticals: new challenges. Health Affairs 2006; 25(5):1363-1370
   Google Scholar
• Aitken M, Bermdt ER, Cutler DM. Prescription drug spending trends in the united states: looking beyond the turning point. Health Affairs 2009; 28(1): w151-w160
   Google Scholar
• Robinson JC. Insurers' strategies for managing the use and cost of biopharmaceuticals. Health Affairs 2006; 25(5): 1205-1217
   Google Scholar
• Carroll J. Flexibility in biologic benefit designs can deliver big rewards. Biotechnology Healthcare 2008 May-June;5(1):52-56
   Google Scholar
• Hargrave E, Hoadley J, Merrell K, Cubanski J. The Henry J. Medicare part D 2008 data spotlight: specialty tiers. Kaiser Family Foundation publication #7711, 2007. Available at: www.kff.org [Last accessed August 2008]
   Google Scholar
• Kaiser/HRET employer health benefits annual survey, 2007. Kaiser Family Foundation publication #7672, 2007
   Google Scholar
• Lu ZJ, Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ and Statistics 1998;80:108-18
   Web of Science ®Google Scholar
• Cutler DM. Declining disability among the elderly. Health Aff (Millwood) 2001;20:11-27
   Web of Science ®Google Scholar
• Gold M, Seigel J, Russell L, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996
   Google Scholar
• Decision Resources, Inc. Immune and inflammatory disorders study #54: asthma. April 2005
   Google Scholar
• Decision Resources, Inc. Onkos study #1: colorectal cancer. November 2005
   Google Scholar
• Decision Resources, Inc. Metabolic disorders study #1: type 2 diabetes. September 2005
   Google Scholar
• U.S. Bureau of the Census. Projected population change in the U.S., by age and sex: 2000 to 2050. Available at: http://www.census.gov/population/www/projections/usinterimproj/natprojtab02b.pdf [Last accessed 20 October 2009]
   Google Scholar
• National Center for Health Statistics. National health interview surveys, 2001–2003. Current prevalence of asthma. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/series/sr10/ser10.htm [Last accessed 20 May 2006]
   Google Scholar
• Center for Health Statistics. Annual mortality statistics, 1992–2002. Available at: http://www.cdc.gov/nchs/deaths.htm [Last accessed 20 October 2009]
   Google Scholar
• Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute asthma symptom utility index. Chest 1998;114:998-1007
   PubMed Web of Science ®Google Scholar
• Fuhlbrigge AL, Adams RJ, Guilbert TW, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002;166:1044-9
   PubMed Web of Science ®Google Scholar
• American Lung Association. Trends in asthma morbidity and mortality, 2005. Available at: http://www.lungusa.org/atf/cf/{7A8D42C2-FCCA-4604-8ADE-7F5D5E762256}/ASTHMA1.PDF [Last accessed 20 October 2009]
   Google Scholar
• Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003;111:1212-8
   PubMed Web of Science ®Google Scholar
• Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936-40
   PubMed Web of Science ®Google Scholar
• American Heart Association. Heart disease and stroke statistics – 2006 update, 2006. Available at: http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.105.171600v1 [Last accessed 20 October 2009]
   Google Scholar
• Complications of diabetes in the United States. National diabetes and statistics, National Diabetes Information Clearinghouse, a service of the National Institute of Diabetes and Digestive and Kidney Disease, 2007. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/#13 [Last accessed 28 August 2008]
   Google Scholar
• Chen TH, Yen MF, Tung TH. A computer simulation model for cost-effectiveness analysis of mass screening for type 2 diabetes mellitus. Diabetes Res Clin Pract 2001;54(Suppl. 1):S37-42
   PubMedGoogle Scholar
• Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32
   PubMed Web of Science ®Google Scholar
• Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002;45:S13-7
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance and epidemiology end results. Available at: http://seer.cancer.gov/ [Last accessed 20 October 2009]
   Google Scholar
• Ness RM, Holmes AM, Klein R, Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol 2000;95:1800-11
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol 2007;4:643-56
   PubMedGoogle Scholar
• Disease states. In: National Heart, Lung and Blood Institute (NHLBI) Fact Book 2007
   Google Scholar
• Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982–2001. Int J Health Care Finance Econ 2005;5:47-73
   PubMedGoogle Scholar
• American Cancer Society. Cancer facts and figures 2008. Available at: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_and_Figures_2008.asp [Last accessed 4 March 2008]
   Google Scholar
• Simon F. Market access for biopharmaceuticals: new challenges. Health Affairs 2006;25(5):1363-70
   Web of Science ®Google Scholar
• Aitken M, Bermdt ER, Cutler DM. Prescription drug spending trends in the United States: looking beyond the turning point. Health Affairs 2009;28(1):w151-w160
   Web of Science ®Google Scholar
• Robinson JC. Insurers’ strategies for managing the use and cost of biopharmaceuticals. Health Affairs 2006;25(5):1205-17
   Web of Science ®Google Scholar